TDOC
Bearish signalScored 2026-09-16 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Teladoc Health, Inc.
- Nom
- Teladoc Health, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Healthcare Information Services
- Bourse
- NYSE
- Capitalisation
- $1.2B
- Employés
- 5,124
- PDG
- Charles Divita
- Site web
- https://www.teladochealth.com
- Marché
- AZTAEVOIMNMNVCROMCLOMDA
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 36 132 titres (~224 160,15 $ US)
- Insiders
- DIVITA CHARLES III
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$460,877
Avg sell (VWAP, 90d window) $6.28 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$98,147 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-11
- Last synced
-
2026-09-17 09:54:31
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-02 | Catapano Joseph Ronald | Sell · S | 655 | $5.65 | $3,703 | Form 4 |
| 2026-09-11 | DIVITA CHARLES III | Sell · S | 17,805 | $6.10 | $108,682 | Form 4 |
| 2026-09-03 | Rodrigues Fernando M. | Sell · S · 10b5-1 | 9,812 | $6.51 | $63,876 | Form 4 |
| 2026-09-02 | Bliss Kelly | Sell · S | 7,357 | $6.30 | $46,356 | Form 4 |
| 2026-09-02 | Catapano Joseph Ronald | Sell · S | 274 | $6.30 | $1,726 | Form 4 |
| 2026-09-02 | DIVITA CHARLES III | Sell · S | 18,327 | $6.30 | $115,478 | Form 4 |
| 2026-09-02 | Nueno Carlos | Sell · S | 6,200 | $6.30 | $39,066 | Form 4 |
| 2026-09-02 | Rodrigues Fernando M. | Sell · S · 10b5-1 | 5,439 | $6.30 | $34,271 | Form 4 |
| 2026-09-02 | Vandervoort Adam C | Sell · S | 7,573 | $6.30 | $47,717 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-06-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2021-11-26 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2021-08-18 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2021-06-21 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-11-19 | Gilbert Ray Cisneros | Purchase | $15,001 - $50,000 |
| 2020-11-17 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-10-13 | Greg Gianforte | Sale (Partial) | $1,001 - $15,000 |
| 2020-07-14 | Donald Sternoff Beyer | Sale (Full) | $15,001 - $50,000 |
| 2020-05-08 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-05-04 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-04-29 | Greg Gianforte | Sale (Partial) | $50,001 - $100,000 |
| 2020-04-27 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-04-27 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-02-14 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-01-28 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-01-09 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2019-12-23 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2019-06-19 | Brad Schneider | Sale (Full) | $250,001 - $500,000 |
| 2019-05-07 | Brad Schneider | Purchase | $50,001 - $100,000 |
| 2018-12-26 | Greg Gianforte | Purchase | $100,001 - $250,000 |
| 2018-05-04 | Brad Schneider | Purchase | $100,001 - $250,000 |
| 2017-06-04 | Brad Schneider | Purchase | $15,001 - $50,000 |
Signal
Bearish signalScored 2026-09-16 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
TDOC presents a mixed financial picture with improving operational metrics (liquidity score 75, fundamentals trend 65), but the near-total absence of a meaningful catalyst (score 20, type NONE) severely limits the…
The first sentence of the analysis written for TDOC on 2026-09-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 2.69 · operating margin -10% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 69.5% | 70.8% | 70.8% | 69.1% | 68.0% | |
| Ebit Margin | -8.5% | -8.1% | -8.1% | -9.0% | -11.8% | |
| Ebitda Margin | 5.8% | 1.2% | 1.7% | -0.3% | -1.5% | |
| Operating Profit Margin | -10.4% | -39.7% | -9.6% | -567.3% | -13.1% | |
| Pretax Profit Margin | -9.3% | -38.7% | -8.4% | -567.7% | -18.9% | |
| Continuous Operations Profit Margin | -7.9% | -39.0% | -8.5% | -567.5% | -21.1% | |
| Net Profit Margin | -7.9% | -39.0% | -8.5% | -567.5% | -21.1% | |
| Bottom Line Profit Margin | -7.9% | -39.0% | -8.5% | -567.5% | -21.1% | |
| Current Ratio | 2.686 | 1.767 | 3.540 | 3.215 | 3.702 | |
| Quick Ratio | 2.592 | 1.727 | 3.470 | 3.075 | 3.481 | |
| Solvency Ratio | 0.095 | -0.376 | 0.016 | -5.620 | -0.131 | |
| Cash Ratio | 1.930 | 1.379 | 2.671 | 2.297 | 2.699 | |
| Price To Earnings Ratio | -6.140 | -1.549 | -15.846 | -0.280 | -33.634 | |
| Price To Earnings Growth Ratio | 0.076 | -0.005 | 0.161 | -0.000 | 0.685 | |
| Forward Price To Earnings Growth Ratio | 0.076 | -0.005 | 0.161 | -0.000 | 0.685 | |
| Price To Earnings Diluted Ratio | -6.140 | -1.549 | -16.082 | -0.280 | -33.634 | |
| Price To Earnings Diluted Growth Ratio | 0.076 | -0.005 | 0.163 | -0.000 | 0.685 | |
| Price To Book Ratio | 0.890 | 1.040 | 1.502 | 1.655 | 0.898 | |
| Price To Sales Ratio | 0.488 | 0.603 | 1.343 | 1.587 | 7.089 | |
| Price To Free Cash Flow Ratio | 4.321 | 5.481 | 18.045 | 22.096 | 77.701 | |
| Price To Operating Cash Flow Ratio | 4.191 | 5.279 | 9.984 | 20.172 | 74.283 | |
| Debt To Assets Ratio | 0.335 | 0.451 | 0.363 | 0.338 | 0.072 | |
| Debt To Equity Ratio | 0.751 | 1.063 | 0.685 | 0.688 | 0.080 | |
| Debt To Capital Ratio | 0.429 | 0.515 | 0.406 | 0.407 | 0.074 | |
| Long Term Debt To Capital Ratio | 0.418 | 0.399 | 0.398 | 0.399 | 0.071 | |
| Financial Leverage Ratio | 2.238 | 2.358 | 1.888 | 2.037 | 1.105 | |
| Working Capital Turnover Ratio | 3.602 | 2.870 | 2.664 | 2.704 | 2.507 | |
| Operating Cash Flow Ratio | 0.727 | 0.312 | 0.832 | 0.474 | 0.586 | |
| Operating Cash Flow Sales Ratio | 0.116 | 0.114 | 0.134 | 0.079 | 0.095 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.970 | 0.963 | 0.553 | 0.913 | 0.956 | |
| Debt Service Coverage Ratio | 5.935 | 0.042 | 1.923 | -0.105 | -0.931 | |
| Interest Coverage Ratio | -13.338 | -42.889 | -11.155 | -622.184 | -3.274 | |
| Short Term Operating Cash Flow Coverage Ratio | 26.670 | 0.533 | 0.000 | 13.927 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.283 | 0.185 | 0.220 | 0.119 | 0.152 | |
| Capital Expenditure Coverage Ratio | 33.100 | 27.218 | 2.239 | 11.486 | 22.731 | |
| Dividend Paid And Capex Coverage Ratio | 33.100 | 27.218 | 2.239 | 11.486 | 22.731 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 10.133 | 57.898 | 90.876 | -595.356 | -470.996 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 69.5% | ▼-1.3% | ▼-0.1% |
| Ebit Margin | -8.5% | ▼-0.4% | ▲0.6% |
| Ebitda Margin | 5.8% | ▲4.6% | ▲4.5% |
| Operating Profit Margin | -10.4% | ▲29.3% | ▲117.6% |
| Pretax Profit Margin | -9.3% | ▲29.4% | ▲119.3% |
| Continuous Operations Profit Margin | -7.9% | ▲31.1% | ▲120.9% |
| Net Profit Margin | -7.9% | ▲31.1% | ▲120.9% |
| Bottom Line Profit Margin | -7.9% | ▲31.1% | ▲120.9% |
| Current Ratio | 2.687 | ▲0.919 | ▼-0.296 |
| Quick Ratio | 2.592 | ▲0.865 | ▼-0.277 |
| Solvency Ratio | 0.095 | ▲0.470 | ▲1.298 |
| Cash Ratio | 1.930 | ▲0.551 | ▼-0.265 |
| Price To Earnings Ratio | -6.140 | ▼-4.592 | ▲5.349 |
| Price To Earnings Growth Ratio | 0.076 | ▲0.081 | ▼-0.107 |
| Forward Price To Earnings Growth Ratio | 0.076 | ▲0.081 | ▼-0.107 |
| Price To Earnings Diluted Ratio | -6.140 | ▼-4.592 | ▲5.396 |
| Price To Earnings Diluted Growth Ratio | 0.076 | ▲0.081 | ▼-0.108 |
| Price To Book Ratio | 0.890 | ▼-0.150 | ▼-0.307 |
| Price To Sales Ratio | 0.488 | ▼-0.116 | ▼-1.734 |
| Price To Free Cash Flow Ratio | 4.321 | ▼-1.159 | ▼-21.208 |
| Price To Operating Cash Flow Ratio | 4.191 | ▼-1.089 | ▼-18.591 |
| Debt To Assets Ratio | 0.336 | ▼-0.115 | ▲0.024 |
| Debt To Equity Ratio | 0.751 | ▼-0.312 | ▲0.098 |
| Debt To Capital Ratio | 0.429 | ▼-0.086 | ▲0.062 |
| Long Term Debt To Capital Ratio | 0.418 | ▲0.019 | ▲0.081 |
| Financial Leverage Ratio | 2.238 | ▼-0.121 | ▲0.312 |
| Working Capital Turnover Ratio | 3.602 | ▲0.732 | ▲0.732 |
| Operating Cash Flow Ratio | 0.727 | ▲0.415 | ▲0.141 |
| Operating Cash Flow Sales Ratio | 0.116 | ▲0.002 | ▲0.009 |
| Free Cash Flow Operating Cash Flow Ratio | 0.970 | ▲0.006 | ▲0.099 |
| Debt Service Coverage Ratio | 5.935 | ▲5.893 | ▲4.562 |
| Interest Coverage Ratio | -13.338 | ▲29.550 | ▲125.230 |
| Short Term Operating Cash Flow Coverage Ratio | 26.670 | ▲26.137 | ▲18.444 |
| Operating Cash Flow Coverage Ratio | 0.283 | ▲0.098 | ▲0.091 |
| Capital Expenditure Coverage Ratio | 33.100 | ▲5.882 | ▲13.745 |
| Dividend Paid And Capex Coverage Ratio | 33.100 | ▲5.882 | ▲13.745 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 10.133 | ▼-47.765 | ▲191.622 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.23B | $1.55B | $3.49B | $3.82B | $14.41B | |
| Enterprise value | $1.49B | $1.84B | $3.96B | $4.49B | $14.80B | |
| EV / Sales | 0.59x | 0.71x | 1.52x | 1.86x | 7.28x | |
| EV / Op. cash flow | 5.07x | 6.25x | 11.32x | 23.70x | 76.28x | |
| EV / Free cash flow | 5.23x | 6.49x | 20.46x | 25.97x | 79.79x | |
| EV / EBITDA | 10.13x | 57.90x | 90.88x | -595.36x | -471.00x | |
| Net debt / EBITDA | 1.76x | 9.03x | 10.74x | -88.73x | -12.31x | |
| Current ratio | 2.69x | 1.77x | 3.54x | 3.21x | 3.70x | |
| Income quality | -1.47x | -0.29x | -1.59x | -0.01x | -0.45x | |
| Graham net-net | -$4 | -$3 | -$5 | -$8 | -$4 | |
| Tax burden | 85.1% | 100.8% | 100.3% | 100.0% | 111.5% | |
| Interest burden | 109.1% | 475.9% | 104.3% | 6283.0% | 161.0% | |
| Working capital | $682.6M | $722.4M | $1.07B | $885.7M | $894.4M | |
| Invested capital | $2.32B | $2.49B | $3.89B | $3.87B | $17.38B | |
| Return on assets | -6.5% | -28.5% | -5.0% | -290.6% | -2.4% | |
| Operating ROA | -7.9% | -25.8% | -5.5% | -121.7% | -1.5% | |
| Return on tangible assets | -13.2% | -55.6% | -13.4% | -762.7% | -32.5% | |
| Return on equity | -14.5% | -67.1% | -9.5% | -591.9% | -2.7% | |
| Return on invested capital | -8.3% | -32.6% | -6.2% | -316.3% | -1.5% | |
| Return on capital employed | -9.8% | -39.6% | -6.3% | -317.4% | -1.5% | |
| Earnings yield | -16.2% | -64.6% | -6.3% | -357.7% | -3.0% | |
| Free cash flow yield | 23.1% | 18.2% | 5.5% | 4.5% | 1.3% | |
| Capex / Op. cash flow | 3.0% | 3.7% | 44.7% | 8.7% | 4.4% | |
| Capex / Depreciation | 2.4% | 2.8% | 44.8% | 6.2% | 3.9% | |
| Capex / Sales | 0.4% | 0.4% | 6.0% | 0.7% | 0.4% | |
| SG&A / Sales | 42.9% | 52.4% | 52.5% | 54.0% | 54.4% | |
| R&D / Sales | 11.0% | 12.0% | 13.4% | 13.9% | 15.3% | |
| Stock comp / Sales | 3.2% | 5.7% | 7.7% | 9.1% | 14.9% | |
| Intangibles / Total assets | 51.0% | 48.8% | 62.6% | 61.9% | 92.6% | |
| Days sales outstanding | 29d | 32d | 32d | 36d | 34d | |
| Days payables outstanding | 23d | 16d | 21d | 23d | 27d | |
| Operating cycle | 47d | 50d | 46d | 63d | 75d | |
| Cash conversion cycle | 24d | 34d | 25d | 40d | 49d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-12 Teladoc: Integrated Care And Free Cash Flow Could Bring It Back To Life Teladoc Health trades near multi-year lows, with the market pricing in deep distress despite meaningful free cash flow and manageable debt. BetterHelp''s rapid decline drags on TDOC, but Integrated Care''s improving margins and growing revenue per member offer stabilization. TDOC''s valuation is extremely depressed, trading at just 7–8x expected free cash flow, with fair value estimates suggesting significant upside even under conservative scenarios.
- 2026-09-11 Why Teladoc (TDOC) Outpaced the Stock Market Today Teladoc (TDOC) reached $6.16 at the closing of the latest trading day, reflecting a +1.15% change compared to its last close.
- 2026-09-09 Dow, Nasdaq Down Triple Digits as Brent Crude Tops July Peak Major Indexes are moving lower once again as investors focus on geopolitical tensions
- 2026-09-08 2 Beaten-Down Stocks to Avoid Right Now Don''t catch a falling knife.
- 2026-09-07 Here''s Why Teladoc''s Integrated Care Business Deserves More Attention TDOC''s Integrated Care is driving profitability as chronic care gains traction, potentially making it the company''s key earnings driver.
- 2026-09-03 Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08 NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to a new employee.
- 2026-09-02 Here''s Why Investors Should Stay Neutral on TDOC Stock for Now Teladoc Health''s growth is supported by chronic care, international expansion and Teladoc One, but BetterHelp weakness and losses temper the outlook.
- 2026-09-01 Connor Clark & Lunn Investment Management Ltd. Buys Shares of 87,511 Teladoc Health, Inc. $TDOC Connor Clark and Lunn Investment Management Ltd. bought a new position in Teladoc Health, Inc. (NYSE: TDOC) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 87,511 shares of the health services provider''s stock, valued at approximately $742,000. Several other hedge funds
- 2026-08-31 Teladoc appoints insurance executive Michael Grasher as CFO Teladoc Health said on Monday it appointed Michael Grasher as its chief financial officer, bringing in an industry veteran to help the virtual healthcare company navigate rising demand for its insurance-covered business.
- 2026-08-31 Teladoc Health Appoints Michael Grasher as Chief Financial Officer Appointment brings seasoned financial leadership as Teladoc Health advances its strategy aimed at delivering disciplined, sustainable growth NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Michael Grasher as Chief Financial Officer, effective immediately. Mr. Grasher is an accomplished financial executive with more than three decades of experience across the insurance and financial services sectors, including more than 12 years in CFO roles at public and privately held companies.